Search

Abstract: We report the fabrication and characterisation of the first graphene ring micro electrodes with the addition of a miniature concentric Ag/AgCl reference electrode. The graphene ring electrode is formed by dip coating fibre optics with graphene produced by a modified Hummers method. The reference electrode is formed using an established photocatalytically initiated electroless deposition (PIED) plating method. The performance of the so-formed graphene ring micro electrodes (GRiMEs) and associated reference electrode is studied using the probe redox system ferricyanide and electrode thicknesses assessed using established electrochemical methods. Using 220 µm diameter fibre optics, a ~15 nm thick graphene ring electrode is obtained corresponding to an inner to outer radius ratio of >0.999, so allowing for use of extant analytical descriptions of very thin ring microelectrodes in data analysis. GRiMEs are highly reliable (current response invariant over >3,000 scans), with the concentric reference electrode showing comparable stability (current response invariant over >300 scans). Furthermore the micro-ring design allows for efficient use of electrochemically active graphene edge sites and the associated nA scale currents obtained neatly obviate issues relating to the high resistivity of undoped graphene. Thus, the use of graphene in ring microelectrodes improves the reliability of existing micro-electrode designs and expands the range of use of graphene-based electrochemical devices.

Influenza vaccine effectiveness (VE) is generally interpreted in the context of vaccine match/mismatch to circulating strains with evolutionary drift in the latter invoked to explain reduced protection. During the 2012-13 season, however, detailed genotypic and phenotypic characterization shows that low VE was instead related to mutations in the egg-adapted H3N2 vaccine strain rather than antigenic drift in circulating viruses.Component-specific VE against medically-attended, PCR-confirmed influenza was estimated in Canada by test-negative case-control design. Influenza A viruses were characterized genotypically by amino acid (AA) sequencing of established haemagglutinin (HA) antigenic sites and phenotypically through haemagglutination inhibition (HI) assay. H3N2 viruses were characterized in relation to the WHO-recommended, cell-passaged vaccine prototype (A/Victoria/361/2011) as well as the egg-adapted strain as per actually used in vaccine production. Among the total of 1501 participants, influenza virus was detected in 652 (43%). Nearly two-thirds of viruses typed/subtyped were A(H3N2) (394/626; 63%); the remainder were A(H1N1)pdm09 (79/626; 13%), B/Yamagata (98/626; 16%) or B/Victoria (54/626; 9%). Suboptimal VE of 50% (95%CI: 33-63%) overall was driven by predominant H3N2 activity for which VE was 41% (95%CI: 17-59%). All H3N2 field isolates were HI-characterized as well-matched to the WHO-recommended A/Victoria/361/2011 prototype whereas all but one were antigenically distinct from the egg-adapted strain as per actually used in vaccine production. The egg-adapted strain was itself antigenically distinct from the WHO-recommended prototype, and bore three AA mutations at antigenic sites B [H156Q, G186V] and D [S219Y]. Conversely, circulating viruses were identical to the WHO-recommended prototype at these positions with other genetic variation that did not affect antigenicity. VE was 59% (95%CI:16-80%) against A(H1N1)pdm09, 67% (95%CI: 30-85%) against B/Yamagata (vaccine-lineage) and 75% (95%CI: 29-91%) against B/Victoria (non-vaccine-lineage) viruses.These findings underscore the need to monitor vaccine viruses as well as circulating strains to explain vaccine performance. Evolutionary drift in circulating viruses cannot be regulated, but influential mutations introduced as part of egg-based vaccine production may be amenable to improvements.

The emotion perceived in a face can be influenced by prior exposure to a face expressing a different emotion. Here we show that displacement along a particular emotional axis, that encoding happiness and sadness, can be effected solely by a systematic change in the angle, at the centre of the mouth, between the left and right halves of the mouth. We then demonstrate that adaptation to a face with the mouth distorted to change this angle, such that the face expresses an emotion on this axis, causes a face with a neutral expression to be perceived as having the opposite expression. By abstracting the mouths from the faces and examining the magnitude of the angle aftereffects in the mouths alone and in an unfamiliar orientation, we show that the magnitudes of the angle aftereffects are sufficient to account for the changes in perceived emotion in the faces. Further, by applying the distortion to the mouths asymmetrically so that the distortion is manifested by a change in orientation of the mouth stimulus rather than a change in angle, we show that the magnitude of the aftereffect can be predicted by the local tilt aftereffect. We argue, therefore, that the aftereffects of emotion are due to misperception of morphology of the face and that the misperception is due to the local change in perceived orientation due to the systematic application of the tilt aftereffect in a tilt aftereffect field. All adaptation experiments were performed using stimuli that were either high-pass or low-pass filtered for spatial frequency. Results showed that the spatial frequency specificity of the aftereffects was the same for the face, angled mouth and oriented mouth stimuli, lending further support to the hypothesis that the aftereffects are instantiated in processes early in the visual cortex and that the aftereffects assumed to be higher level are, in fact, inherited.

BackgroundIn late spring 2009, concern was raised in Canada that prior vaccination with the 2008-09 trivalent inactivated influenza vaccine (TIV) was associated with increased risk of pandemic influenza A (H1N1) (pH1N1) illness. Several epidemiologic investigations were conducted through the summer to assess this putative association.Methods and findingsStudies included(1) test-negative case-control design based on Canada's sentinel vaccine effectiveness monitoring system in British Columbia, Alberta, Ontario, and Quebec; (2) conventional case-control design using population controls in Quebec; (3) test-negative case-control design in Ontario; and (4) prospective household transmission (cohort) study in Quebec. Logistic regression was used to estimate odds ratios for TIV effect on community- or hospital-based laboratory-confirmed seasonal or pH1N1 influenza cases compared to controls with restriction, stratification, and adjustment for covariates including combinations of age, sex, comorbidity, timeliness of medical visit, prior physician visits, and/or health care worker (HCW) status. For the prospective study risk ratios were computed. Based on the sentinel study of 672 cases and 857 controls, 2008-09 TIV was associated with statistically significant protection against seasonal influenza (odds ratio 0.44, 95% CI 0.33-0.59). In contrast, estimates from the sentinel and three other observational studies, involving a total of 1,226 laboratory-confirmed pH1N1 cases and 1,505 controls, indicated that prior receipt of 2008-09 TIV was associated with increased risk of medically attended pH1N1 illness during the spring-summer 2009, with estimated risk or odds ratios ranging from 1.4 to 2.5. Risk of pH1N1 hospitalization was not further increased among vaccinated people when comparing hospitalized to community cases.ConclusionsPrior receipt of 2008-09 TIV was associated with increased risk of medically attended pH1N1 illness during the spring-summer 2009 in Canada. The occurrence of bias (selection, information) or confounding cannot be ruled out. Further experimental and epidemiological assessment is warranted. Possible biological mechanisms and immunoepidemiologic implications are considered.